The ratings of three Pharmaceutical stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, VIVUS, Inc. (NASDAQ:VVUS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. For Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. The stock price has dropped 26.4% over the past month, worse than the 1.3% decrease the Nasdaq has seen over the same period of time. As of Nov. 8, 2013, 29.8% of outstanding VIVUS, Inc. shares were held short. To get an in-depth look at VVUS, get Portfolio Grader’s complete analysis of VVUS stock.
Cempra, Inc. (NASDAQ:CEMP) gets weaker ratings this week as last week’s C drops to a D. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of CEMP stock.
Corcept Therapeutics Incorporated. (NASDAQ:CORT) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. For a full analysis of CORT stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.